{
  "created_at": "Wed Jul 14 2:59:50 +0000 2021",
  "id_str": "1414882556567334915",
  "full_text": "The agreement for 20m doses of Covaxin was signed by Brazil’s health ministry in February for a price 50% higher than was offered three months earlier by the jab’s developer, Bharat Biotech. Both companies deny any wrongdoing https://t.co/QEq2wrnhuN",
  "display_text_range": [
    0,
    249
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/QEq2wrnhuN",
        "expanded_url": "https://econ.st/3dWLB4n",
        "display_url": "econ.st/3dWLB4n",
        "indices": [
          226,
          249
        ]
      }
    ]
  },
  "user": {
    "name": "The Economist",
    "screen_name": "TheEconomist",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/879361767914262528/HdRauDM-_normal.jpg"
  },
  "retweet_count": 35,
  "favorite_count": 81,
  "possibly_sensitive": false,
  "original_created_at": "Tue Jul 13 09:41:03 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "コバクシン2,000万回分の契約は、ブラジル保健省が2月に締結したもので、その価格は3ヶ月前に開発元のバラット・バイオテック社が提示した価格の50％増しとなっています。両社は不正行為を否定している。https://t.co/QEq2wrnhuN"
    },
    {
      "locale": "zh",
      "full_text": "巴西卫生部于2月签署了2000万剂Covaxin的协议，价格比三个月前该疫苗开发商Bharat Biotech提供的价格高50%。两家公司都否认有任何不当行为 https://t.co/QEq2wrnhuN"
    },
    {
      "locale": "zh-Hant",
      "full_text": "巴西衛生部於2月簽署了2000萬劑Covaxin的協議，價格比三個月前該疫苗開發商Bharat Biotech提供的價格高50%。兩家公司都否認有任何不當行爲 https://t.co/QEq2wrnhuN"
    }
  ]
}